Company PHAXIAM Therapeutics S.A. Deutsche Boerse AG

Equities

2E40

FR001400K4B1

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Deutsche Boerse AG Other stock markets 20:41:05 28/06/2024 BST			5-day change	1st Jan Change
1.89 ^EUR	-9.79%		-3.57%	-57.53%

06-28	Would you like some more inflation?
06-28	Phaxiam: fewer funds raised than expected	CF

PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.

Number of employees: 68

Managers	Title	Age	Since
Thibaut du Fayet CEO	Chief Executive Officer	56	22/06/23
Eric Soyer DFI	Director of Finance/CFO	57	22/06/23
Pascal Birman CTO	Chief Tech/Sci/R&D Officer	-	22/06/23
Cindy Fevre CTO	Chief Tech/Sci/R&D Officer	-	22/06/23
Céline Breda CTO	Chief Tech/Sci/R&D Officer	54	22/06/23
Karine Charton PRN	Corporate Officer/Principal	-	22/06/23
Frédérique Vieville LAW	General Counsel	-	22/06/23
Anne-Cécile Fumey HRO	Human Resources Officer	-	22/06/23
Jérôme Bailly PRN	Corporate Officer/Principal	45	22/06/23

Members of the board	Title	Age	Since
Philippe Archinard BRD	Director/Board Member	63	22/06/23
Hilde Windels BRD	Director/Board Member	59	22/06/23
Gil Beyen BRD	Director/Board Member	62	22/06/23
Martine George BRD	Director/Board Member	76	22/06/23
Eric Jean Marie Leire BRD	Director/Board Member	66	22/06/23
Didier Hoch CHM	Chairman	68	22/06/23
Leila Nicolas BRD	Director/Board Member	-	22/06/23
Robert Sebbag BRD	Director/Board Member	73	22/06/23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	11,137,712	10,660,161 ( 95.71 %)	270 ( 0.002429 %)	95.71 %

Name	Equities	%	Valuation
Armistice Capital LLC 2.682 %	162,912	2.682 %	529 687 €
Auriga Partners SA 1.889 %	114,752	1.889 %	373 101 €
RECORDATI 0.7095 %	43,103	0.7095 %	140 144 €
OFI Invest Asset Management SA 0.2780 %	16,886	0.2780 %	54 903 €
BVF Partners LP 0.1602 %	9,734	0.1602 %	31 649 €
Generali Asset Management SGR SpA 0.1152 %	7,000	0.1152 %	22 760 €
Friedland Gestion SAS 0.0556 %	3,375	0.0556 %	10 973 €
Philippe Archinard 0.0170 %	1,030	0.0170 %	3 349 €
Eric Soyer 0.0103 %	626	0.0103 %	2 035 €
Gil Beyen 0.007967 %	484	0.007967 %	1 574 €

Name	Equities	%	Valuation
Asset Dedication LLC 0.000000 %	0	0.000000 %	- €

Name	Equities	%	Valuation
PHAXIAM THERAPEUTICS S.A. 0.00%	250	0.00%	813 $

PHAXIAM Therapeutics SA

60, avenue Rockefeller Bâtiment Bioserra

69008, Lyon

http://www.phaxiam.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.99 EUR

Average target price

5.1 EUR

Spread / Average Target

+156.28%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs